SUBSEQUENT EVENTS	3 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS In accordance with ASC 855, the following information below are subsequent transactions from the end of the June 30, 2026 reporting period to the date of this filing on August 14, 2026. In July 2026, the Company issued 156,250 shares of restricted stock for the conversion of accrued dividends on Series B Preferred Stock valued at $125,000. In July 2026, the Company issued 200,000 shares of restricted stock to employees for performance bonuses valued at market on the date of grant of $160,000 and expense in the current period. On July 9, 2026, the Company received proceeds of $100,000 on a promissory note with a maturity date of January 9, 2027 and an accrued interest rate of 6% per annum with no conversion provisions. On July 24, 2026, the Company terminated the VetStem, Inc. licensing agreement. With the licensing termination, the Company is obligated to pay a fee of $75,000 in lieu of any liabilities to be waived and the return of any remaining PRP inventory on July 24, 2026. On July 27, 2026, the Company received proceeds of $130,000 on a promissory note with a maturity date of July 27, 2027 and an accrued interest rate of 6% per annum with no conversion provisions. Between August 7 through August 11, 2026, the Company received proceeds of $150,000 on a promissory note with a maturity date of August 7, 2027 and an accrued interest rate of 10% per annum with no conversion provisions. On August 11, 2026, the Company received proceeds of $50,000 on a promissory note with a maturity date of November 11, 2026 and an accrued interest rate of 10% per annum with no conversion provisions. On August 13, 2026, 2,875,000 of the February 9, 2022 registered tradeable warrants, trading under the ticker symbol “PETVW” expired, pursuant to the terms of the warrant.

SUBSEQUENT EVENTS

3 Months Ended

Jun. 30, 2026

NOTE 17 – SUBSEQUENT EVENTS

In accordance with ASC 855, the following information below are subsequent transactions from the end of the June 30, 2026 reporting period to the date of this filing on August 14, 2026.

In July 2026, the Company issued 156,250 shares of restricted stock for the conversion of accrued dividends on Series B Preferred Stock valued at $125,000.

In July 2026, the Company issued 200,000 shares of restricted stock to employees for performance bonuses valued at market on the date of grant of $160,000 and expense in the current period.

On July 9, 2026, the Company received proceeds of $100,000 on a promissory note with a maturity date of January 9, 2027 and an accrued interest rate of 6% per annum with no conversion provisions.

On July 24, 2026, the Company terminated the VetStem, Inc. licensing agreement. With the licensing termination, the Company is obligated to pay a fee of $75,000 in lieu of any liabilities to be waived and the return of any remaining PRP inventory on July 24, 2026.

On July 27, 2026, the Company received proceeds of $130,000 on a promissory note with a maturity date of July 27, 2027 and an accrued interest rate of 6% per annum with no conversion provisions.

Between August 7 through August 11, 2026, the Company received proceeds of $150,000 on a promissory note with a maturity date of August 7, 2027 and an accrued interest rate of 10% per annum with no conversion provisions.

On August 11, 2026, the Company received proceeds of $50,000 on a promissory note with a maturity date of November 11, 2026 and an accrued interest rate of 10% per annum with no conversion provisions.

On August 13, 2026, 2,875,000 of the February 9, 2022 registered tradeable warrants, trading under the ticker symbol “PETVW” expired, pursuant to the terms of the warrant.